SRR8518412
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.420
- ESTROGEN_RESPONSE_LATE+0.350
- OXIDATIVE_PHOSPHORYLATION+0.340
- DNA_REPAIR+0.310
- E2F_TARGETS+0.300
- MYC_TARGETS_V2+0.250
- MYC_TARGETS_V1+0.210
- SPERMATOGENESIS+0.200
- BILE_ACID_METABOLISM+0.180
- PEROXISOME+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.660
- HEDGEHOG_SIGNALING-0.460
- TNFA_SIGNALING_VIA_NFKB-0.440
- INFLAMMATORY_RESPONSE-0.430
- ANGIOGENESIS-0.390
- IL6_JAK_STAT3_SIGNALING-0.390
- KRAS_SIGNALING_UP-0.390
- COAGULATION-0.360
- APICAL_JUNCTION-0.350
- HYPOXIA-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20070010.LumB | — | B | 0.932 |
| 2 | TCGA-5T-A9QA-01A-11R-A41B-07 | — | B | 0.896 |
| 3 | MBCProject_0076_T1_RNA | — | B | 0.889 |
| 4 | 20050053.LumB | — | B | 0.886 |
| 5 | 20110028.LumB | — | B | 0.882 |
| 6 | BSR_15_0056_E1_S102 | — | B | 0.877 |
| 7 | TCGA-AO-A0J3-01A-11R-A034-07 | — | B | 0.872 |
| 8 | BSR_04_0040_A3_S71 | — | B | 0.870 |
| 9 | TCGA-S3-A6ZH-01A-22R-A32P-07 | — | B | 0.867 |
| 10 | 20120289.LumB | — | B | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.420 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |